Form 4: Janux Therapeutics Director Simson Jake Receives Stock Options and Restricted Stock Units

Director Simson Jake received stock options and restricted stock units from Janux Therapeutics, but disclaims beneficial ownership due to an arrangement with RA Capital Management.

Summary

• On June 26, 2024, Janux Therapeutics director Jake Simson received 2,500 restricted stock units (RSUs) and an option to purchase 8,350 shares of common stock.
• The RSUs will vest on the earlier of June 26, 2025, or the date of the next annual meeting of the Issuer's stockholders, subject to continuous service.
• The stock options, with an exercise price of $39.80, vest in equal monthly installments over 12 months following June 26, 2024, but will be fully vested by the date of the next annual meeting, subject to continuous service.
• Simson disclaims beneficial ownership of these securities because they are held for the benefit of RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund II, L.P., under an arrangement with RA Capital Management, L.P.
• Any cash or stock received from the exercise of the option or settlement of RSUs will offset advisory fees owed by the Funds to the Advisor.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock options and RSUs granted to a director. The arrangement with RA Capital Management introduces a slight element of caution.

Positives

• The grant of RSUs and stock options to a director aligns their interests with the company's success.
• The vesting schedules for both RSUs and stock options incentivize continued service and commitment from the director.

Risks

• The director disclaims beneficial ownership, suggesting the securities are primarily for the benefit of RA Capital Management, L.P., which could reduce the direct alignment of the director's personal financial interests with the company's performance.

Industry Context

This Form 4 filing is a routine disclosure of equity-based compensation for a company director, which is common in the biotechnology industry to incentivize and retain key personnel. The arrangement with RA Capital Management is less typical and warrants attention.

Comparison to Industry Standards

• Equity compensation for directors is a standard practice in the biotech industry.
• Companies like Amgen, Gilead, and Regeneron routinely grant stock options and RSUs to their directors as part of their compensation packages.
• The vesting schedules and exercise prices are generally aligned with industry norms to incentivize long-term value creation.
• However, the arrangement where the director disclaims beneficial ownership and the securities benefit a fund is less common and could be viewed as unusual.

Stakeholder Impact

• Shareholders may view the equity grants as a positive incentive for the director.
• The arrangement with RA Capital Management could raise questions about the director's direct alignment with shareholder interests.

Key Dates